Tetrylammonium

Tetrylammonium

SCHEMBL228998

CC[N+](CC)(CC)CC.O.[Cl-]

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Tetrylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.90
PMP22 Q01453 1/20 0.90
ATM Q13315 1/20 0.90
TSHR P16473 2/20 0.80
NFKB1 P19838 1/20 0.80
KCNA1 Q09470 1/20 0.80
DNM1 Q05193 4/20 0.37
SLC22A1 O15245 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrylammonium SCHEMBL27437383 0.95 KDM4E (0.82) KDM4EPMP22ATMTSHRNFKB1
Tetrylammonium SCHEMBL352577 0.95 KDM4E (0.82) KDM4EPMP22ATMTSHRNFKB1
Tetrylammonium SCHEMBL5374883 0.95 KDM4E (1.00) KDM4EPMP22ATMTSHRNFKB1
Tetrylammonium SCHEMBL5142182 0.95 TSHR (0.89) KDM4EPMP22ATMTSHRNFKB1
Tetrylammonium SCHEMBL616647 0.95 TSHR (0.89) KDM4EPMP22ATMTSHRNFKB1
Tetrylammonium SCHEMBL1035999 0.95 TSHR (0.89) KDM4EPMP22ATMTSHRNFKB1
Tetrylammonium SCHEMBL10982449 0.95 KDM4E (1.00) KDM4EPMP22ATMTSHRNFKB1
Tetrylammonium SCHEMBL3722218 0.95 TSHR (0.89) KDM4EPMP22ATMTSHRNFKB1
Tetrylammonium SCHEMBL49847 0.95 KDM4E (1.00) KDM4EPMP22ATMTSHRNFKB1
Tetrylammonium SCHEMBL8341373 0.90 TSHR (0.80) KDM4EPMP22ATMTSHRNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177885-A1 COMPOSITION, SYSTEM AND METHOD FOR REMOVAL OF DETERGENTS FROM AQUEOUS SOLUTIONS DNA GENOTEK INC. (CA) 2025-06-05 US claimed
US-12214299-B2 Composition, system and method for removal of detergents from aqueous solutions DNA GENOTEK INC. (CA) 2025-02-04 US claimed
CN-118767993-A Process for deactivation of olefin oligomerization catalysts 沙特基础工业全球技术有限公司 2024-10-15 CN claimed
EP-3350143-B1 PROCESS FOR DEACTIVATION OF AN OLEFIN OLIGOMERIZATION CATALYST SABIC GLOBAL TECHNOLOGIES BV (NL) 2024-05-15 EP claimed
US-20200316493-A1 A COMPOSITION, SYSTEM AND METHOD FOR REMOVAL OF DETERGENTS FROM AQUEOUS SOLUTIONS DNA GENOTEK INC. (CA) 2020-10-08 US claimed
US-10407359-B2 Process for deactivation of an olefin oligomerization catalyst SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2019-09-10 US claimed
EP-3464589-A1 A COMPOSITION, SYSTEM AND METHOD FOR REMOVAL OF DETERGENTS FROM AQUEOUS SOLUTIONS DNA Genotek Inc. (CA) 2019-04-10 EP claimed
EP-3433010-A1 METHOD FOR PROCESSING AN OLIGOMERIZATION PRODUCT STREAM SABIC Global Technologies B.V. (NL) 2019-01-30 EP claimed
US-20180258009-A1 PROCESS FOR DEACTIVATION OF AN OLEFIN OLIGOMERIZATION CATALYST SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2018-09-13 US claimed
EP-3350143-A1 PROCESS FOR DEACTIVATION OF AN OLEFIN OLIGOMERIZATION CATALYST SABIC Global Technologies B.V. (NL) 2018-07-25 EP claimed
US-9018431-B2 Catalyst composition and process for oligomerization of ethylene SAUDI BASIC INDUSTRIES CORPORATION (SA) 2015-04-28 US claimed
US-20120029258-A1 Catalyst Composition and Process for Oligomerization of Ethylene SAUDI BASIC INDUSTRIES CORPORATION (SA) 2012-02-02 US claimed
EP-2239056-B1 Catalyst composition and process for oligomerization of ethylene SAUDI BASIC IND CORP (SA) 2011-07-20 EP claimed
WO-2010115520-A1 CATALYST COMPOSITION AND PROCESS FOR OLIGOMERIZATION OF ETHYLENE LINDE AG (DE) 2010-10-14 WO claimed
EP-2239056-A1 Catalyst composition and process for oligomerization of ethylene Saudi Basic Industries Corporation (SA) 2010-10-13 EP claimed
US-6344563-B1 SULFIDING, DEHYDROHALOGENATION, FORMATION OF BOND BETWEEN CARBON AND NITROGEN NORRIS TIMOTHY (US) 2002-02-05 US claimed
CN-1291609-A Method of preparing 5-lipoxidase inhibitor possessing different heterocyclic ring system PFIZER PROD INC (US) 2001-04-18 CN claimed
EP-1081146-A1 Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems Pfizer Products Inc. (US) 2001-03-07 EP claimed
EP-1081144-A2 Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems Pfizer Products Inc. (US) 2001-03-07 EP claimed
US-6136972-A Preparation of a mannich base intermediate for 2-[(4-heterocyclic-phenoxymethyl)-phenoxy]-alkanoates FMC CORPORATION (US) 2000-10-24 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180258009-A1 PROCESS FOR DEACTIVATION OF AN OLEFIN OLIGOMERIZATION CATALYST ADH1A, ADH1C, MAX KDM4E 4509/4885PMP22 3583/4885ATM 1253/4885
US-10407359-B2 Process for deactivation of an olefin oligomerization catalyst ADH1A, ADH1C, MAX KDM4E 4509/4885PMP22 3583/4885ATM 1253/4885
US-20120029258-A1 Catalyst Composition and Process for Oligomerization of Ethylene TRRAP, CECR2, C1R KDM4E 2898/4885PMP22 2444/4885ATM 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.